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1. Introduction 
Leishmaniasis is a complex disease caused by several species of the Leishmania genus 
ranging in severity from cutaneous and mucocutaneous lesions to the chronic visceral form 
that if untreated adequately can cause death. It has a worldwide distribution in 98 countries 
and 85 out of 98 are developing or poor countries. One of the main problems in 
leishmaniasis is the limited number of drug options along with the adverse effects they can 
cause including death (Ahasan., et al. 1996; Sundar & Chakravarty 2010; Oliveira., et al. 
2011). In addition, there are reports of treatment failures due to increased parasite resistance 
to the first drug of choice, the antimonials (Faraut-Gambarelli., et al. 1997; Goyeneche-
Patino., et al. 2008). Second-choice drugs, such as amphotericin B, pentamidine, 
paromomycin, and more recently, miltefosine, have also toxic effects that require hospital 
management (Maltezou 2008; Oliveira., et al. 2011). Miltefosine, the only oral administered 
drug for leishmaniasis, has not been tested in many Leishmania species. Recently, a central 
nervous system toxicity was reported for liposomal amphotericin B therapy used to treat 
cutaneous leishmaniasis (Glasser & Murray 2011). 
In the search for new drug targets in Leishmania, a group of proteins have been proposed 
based mainly on their known function, the expression level, and localization, or because 
they are involved in important metabolic processes in the parasite. Topoisomerases (Das., et 
al. 2008), kinases (de Azevedo & Soares 2009), proteins localized or targeted to lysosomes 
(Carrero-Lerida., et al. 2009) are some potential Leishmania drug targets. However, none of 
these protein targets have been used to successfully develop new drugs that can substitute 
the existing therapies. 
Currently, the massive genome sequencing of many medically important microorganisms 
together with protein structure and drug databases and the development of new 
computational tools, will allow molecular targets and new drugs to be searched in a more 
rigorous manner. Three Leishmania genomes, L. major, L. infantum and L. braziliensis 
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(Peacock., et al. 2007) have been sequenced and annotated and a fourth species, L. mexicana 
and some L. major strains are in the process of being sequenced (GeneDB, 
http://www.genedb.org; University of Washington Genome Sequencing Center, 
http://genome.wustl.edu/gsc/gschmpg.html). The availability of these genomes and the 
annotated proteins can be used in a rational manner to predict novel drug targets and 
provide a basis to develop new drugs. 
The computational prediction of drugs, in addition to the evaluation of drugs already 
synthesized and used in other diseases, must be coupled with automated in vitro 
assessment methodologies of these compounds. In this sense and in the case of Leishmania, 
the use of GFP (Varela., et al. 2009) or luciferase transgenic parasites (Lang., et al. 2005) 
coupled with techniques such as flow cytometry or fluorometry can be used to rapidly 
evaluate potential anti-leishmanial drugs. The WHO program for training in tropical 
diseases research has created a network based on reporter gene technology to foster the 
process of drug search not only against leishmaniasis but also against other diseases with 
limited therapeutic options. 
2. Selection of drug targets 
An initial step in the drug discovery process involves the search and selection of the drug 
target. This target is frequently a protein that is essential for the organism survival or critical 
for regulating a particular signaling pathway. In the specific case of parasites, the protein 
target when inhibited should impair or delay parasite viability. The classical approach of 
finding a new essential protein that can act as a potential target is the experimental 
characterization by using gene knockout or knock-down strategies in the target organism. 
Besides essentiality, some targets are selected for being specific for the pathogen; for example, 
the ergosterol pathway is present in fungi and Leishmania spp, but humans only contain the 
required enzymes for the synthesis of cholesterol. This is the reason why this pathway has 
been exploited for searching drugs against mycotic pathogens and also Leishmania. However, 
the experimental approach employing interference RNA (RNAi) is not feasible given 
Leishmania species do not carry the machinery for RNAi (Peacock., et al. 2007), with the 
exception of Leishmania braziliensis where some RNAi-associated genes have been found. In 
addition, depending on the parasite stage the essentiality of a particular protein could change 
dramatically. With all these constraints, a rational alternative for choosing effective targets is a 
more systematic study of the biology of the parasite, with the aim of uncovering important 
mechanisms that are not evident by studying descriptively isolated proteins. A starting point 
for this “systems view” of the parasite biology in the case of Leishmania, was the sequencing of 
its genome in 2005 (Ivens., et al. 2005). Since then, more high-throughput data have been 
generated, not at the same rate as other organisms but with important applications for drug 
discovery in tropical diseases. This leads to an important issue of data analysis, where 
computational tools can have a role in reducing the ocean of possibilities of finding a drug for 
this disease, making more efficient and less costly the experimental setup. In the following 
sections, we will describe the current computational methods that can be applied to find new 
drug targets, with special application to the Leishmania parasite. 
2.1 Selection of targets by homology searching 
The simplest approach for finding a drug target is the homology search of essential proteins. 
There are several organisms with available essential data at genome-wide level (Forsyth., et 
al. 2002; Kamath., et al. 2003; Hu., et al. 2007). In model organisms such as yeast, the 
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phenotypic effects of deletion of particular genes have been shown (Giaever., et al. 2002) and 
more recently the study of genetic interactions on a large scale (Costanzo., et al. 2010). This 
has been used to elucidate redundancy and possibly some synergistic effects among genes. 
Therefore, it is possible to find orthologs in the organism of interest that could be essential 
by comparing its sequences against the list of essential genes in model organisms. The 
Database of Essential Genes (http://tubic.tju.edu.cn/deg/) (Zhang & Lin 2009) provides 
information of essential genes in prokaryotes and eukaryotes, and it is also possible to do a 
BLAST search with the protein of interest. This resource is useful for an exploratory search 
of essentiality of a particular protein. Another important resource, for drug target data, is 
the DrugBank database (http://www.drugbank.ca/) (Knox., et al. 2011), which can be used 
to extract drug-target interactions along with additional pharmacological data. The same 
strategy can be employed in this case; with the advantage that the homology search will also 
return possible drug candidates that can be tested on the protein found to have homology to 
the target in DrugBank. 
This methodology has been applied in Pseudomonas aeruginosa (Sakharkar., et al. 2004) with 
the aim of detecting new drug targets, given this bacterium is an important problem in 
nosocomial settings due to the rapid generation of resistance. In Leishmania, drug targets can 
be also identified by this approach. Tools like BLAST or PSI-BLAST can be employed, with 
PSI-BLAST being more sensitive for detecting distant relationships among proteins 
(Altschul., et al. 1997). However, some false positives still can occur due to alignments that 
are optimal according to the algorithm but not biologically meaningful. The E value helps to 
detect those alignments that are significant. As an example, running a PSI-BLAST search 
with the Leishmania major proteome against the DrugBank database, one can find among the 
potential Leishmania orthologs to known targets, the protein LmjF36.2430, which is similar to 
the sterol 14- alpha demethylase in fungi. Drugs such as miconazole are known inhibitors of 
this enzyme. Interestingly, the protein LmjF19.0450 belongs to the group of protein kinases 
conserved in other Leishmania species; it is constitutively expressed and has significant 
similarity to other kinase targets in cancer. These are simple cases of how a homology search 
can generate a list of potential drug targets using existing genomic data. The main 
advantage of this methodology is that it offers a quick overview of potential targets and 
second use of drugs. In addition, the STITCH 2 database (http://stitch.embl.de/) (Kuhn., et 
al. 2010) compiles known and predicted drug-target relationships jointly with biological 
information about targets in a network-based view. 
Despite its simplicity, the homology search strategy has some caveats. Proteins inside the 
cell perform specific functions depending on their interactions, and these interactions can 
vary between species. Even if sequences are highly related, pathway conservation is not 
necessarily present. In addition, temporal regulation is important, as not all the interactions 
are active at the same time, which can further complicate the analysis. These problems 
highlight the importance of detecting targets by incorporating more detailed information 
about the molecular interactions. 
2.2 Selection of targets by topological analysis of protein networks 
In order to better understand complex pathogens such as Leishmania and to improve the 
efficiency of the drug discovery process, it is crucial to gain deeper knowledge about how 
protein interactions are established and how these interactions are regulated. This is a 
central issue for a more accurate definition of essentiality and biological robustness. These 
interactions can be described as a network, a representation commonly used to describe 
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complex systems. The protein interaction network (interactome) describes all possible 
molecular interactions among proteins. The interactome is composed of nodes that represent 
the molecular components, in this case proteins, and edges, that are the interactions between 
components (Fig. 1). Depending on the biological function of the node, other types of 
networks can also be constructed; for example, gene networks involving transcription 
factors as nodes that regulate other genes by binding (edges) and metabolic networks where 
the nodes are the enzymes connected by the production of some metabolites. The study of 
networks comes from a mathematical discipline called graph theory, and the analysis of the 
interaction patterns in the network is defined as network topology.(Barabasi & Oltvai 2004) 
 
 
Fig. 1. Schematic representation of a protein network. Yellow circle corresponds to a hub 
protein, green circles correspond to bottleneck proteins connecting several sub-networks. 
Lines connecting circles represent the edges of the network.  
To detect protein interactions in biological systems, large-scale methods have been 
developed that can map all possible pairwise interactions. Yeast two-hybrid is a popular 
technique of this kind, which was used to construct the first interactome (Uetz., et al. 
2000). The technique involves the fusion of a protein with a transcription factor DNA-
binding domain subunit. This protein is called the bait. The second protein is fused onto 
an activator domain subunit and it is called the prey. If the interaction between the bait 
and the prey is present, the two transcription factor subunits will come closer and the 
expression of the reporter gene is activated (Osman 2004). The most important limitation 
of this method is the presence of high number of false positives. However recent evidence 
has shown that a combination of experimental methods will reduce the number of false 
interactions (Dreze., et al. 2010). 
The initial studies of the yeast interactome revealed that the network structure was not 
organized randomly, and in fact the organization pattern was similar to other 
experimentally-observed networks. This particular network structure was called scale-free 
www.intechopen.com
 
Current Advances in Computational Strategies for Drug Discovery in Leishmaniasis 
 
257 
and it was elucidated by analyzing the number of interactions (or degree distribution) of 
proteins in the yeast interactome, showing that some nodes were more highly connected 
than others, and those nodes were in relatively low frequency in the network. This scale-free 
structure followed a power law distribution for the node degree and it described the 
probability of a node having a certain degree. An interesting consequence of having a scale-
free structure is that the network was robust against random deletion of nodes, but  
susceptible to the deletion of highly connected nodes or hubs (Jeong., et al. 2001). The hubs 
can be detected by measuring the connectivity or degree of the network. In addition, the 
scale-free network was also susceptible to deletion of other types of nodes that were not 
highly connected but control the flux of the network; these nodes were called bottlenecks 
(Yu., et al. 2007). A classical example of bottleneck nodes is the scaffold proteins (Good., et 
al. 2011); these proteins facilitate the communication between signalling pathways very 
efficiently, although sometimes they are not highly connected. Deleting a bottleneck node 
will disrupt cellular homeostasis by destroying communication between processes in the 
cell. This network biology approach becomes an important step in a systems level 
understanding of the biology of parasites like Leishmania, and it becomes very useful for 
detecting essential nodes that may constitute potential new drug targets. 
2.2.1 Construction of the Leishmania protein interaction network 
The analysis of the Leishmania protein network could lead to the discovery of new and 
effective drug targets. However, current protein interaction data in Leishmania have only 
focused on a few specific proteins, and at this time, no yeast two-hybrid data is available for 
this organism. Despite this limitation, the use of a computationally-predicted protein 
network from orthology-based methods is a good first step for the exploration of drug 
targets that may be more informative than a traditional homology search. The results 
described in the next section will focus on the current status of the predicted Leishmania 
major interactome and will give some directions for future experimental studies for network 
and target validation. 
Even when protein domain sequences are conserved, multiple combinations of these domains 
enable an organism to rewire the interactome in different ways. This can overcome the 
problem of the context of the targets that influence essentiality and enable new hubs or protein 
targets to be detected. A common disadvantage is the bias towards detection of conserved 
interactions, which could be a caveat in the case of organism-specific interactions that may also 
be important for survival. These specific interactions will be only detected when more data 
becomes available, which will also allow existent predictions to be validated.  
In our recent study (Florez., et al. 2010), the protein interaction network in Leishmania major 
was predicted using only the parasite protein sequences and several protein interaction 
databases, in particular iPfam (Finn., et al. 2005), PSIMAP (Park., et al. 2005) and PEIMAP. 
These databases included protein-protein interactions defined by analysis of structures of 
protein complexes and experimental data extracted from literature, including high-
throughput experiments. From the structures, the analysis of interacting structural domains 
was mapped to the sequence, using the domain definition by Pfam (Finn., et al. 2006) and 
SCOP (Hubbard., et al. 1997). These two databases contained information of domains with a 
systematic classification for protein families. In this particular case the physical distance 
between adjacent domains within a complex was used as the criteria for the definition of 
interaction and it was stored in iPfam and PSIMAP databases. This strategy has been used 
www.intechopen.com
 
Current Topics in Tropical Medicine 
 
258 
in other organisms such as fungi and bacteria (He., et al. 2008; Kim., et al. 2008). The domain 
interaction analysis generated more diversity in the detection of possible interactions 
because modular exchange of protein domains allowed rewiring the network even if the 
isolated sequence of the domain was conserved. However, despite the high accuracy of this 
method, the prediction of protein interactions was limited as there was not an abundance of 
crystallized protein complexes. The PEIMAP database was also used, and it included 
sequences of protein interaction pairs detected by several methods, including co-
immunoprecipitation (co-IP) and yeast two-hybrid.  
To construct the Leishmania major network, protein sequences were extracted from the 
GeneDB database. This database included genomic and proteomic information of 
pathogens, including protozoan parasites. The protein sequences were aligned to the 
interacting domain pairs using PSI-BLAST against the SCOP 1.71 database with an E-value 
cutoff of 0.0001, as described previously (Kim., et al. 2008). The PSI-BLAST tool was used for 
the alignments because it had the advantage of detecting small conserved sequences, such as 
small domains that would be otherwise missed by using the standard BLASTP. The same 
strategy was applied for the alignments concerning the iPfam database. In this case, the 
domain assignment for the Leishmania proteins was carried out using the Pfam database 
(release 18.0) with the hmmpfam tool employed for the alignments. The final set of 
predicted interactions was carried out by homology search over the PEIMAP database using 
BLASTP, with a minimal cutoff of 40% sequence identity and 70% length coverage. The 
PEIMAP database included protein-protein interaction (PPI) information from six source 
databases: DIP (Xenarios., et al. 2000), BIND (Bader., et al. 2001), IntAct (Hermjakob., et al. 
2004), MINT (Zanzoni., et al. 2002), HPRD(Peri., et al. 2004), and BioGrid (Stark., et al. 2006).  
2.2.2 Filtering interactions by using a combined confidence score 
As discussed earlier, the reliability of this analysis and its bias to certain types of protein 
interactions was dependent on the experimental method employed. Therefore, it was 
necessary to combine results from different databases to increase the coverage and the 
confidence of the predicted interactions. In the Leishmania major interactome, we used a 
simple scoring system to identify high confidence interactions. A previous study classified 
the experimental methods according to their reliability (Chua., et al. 2006), and we used this 
data in addition to the significance of the sequence alignments to calculate the confidence of 
the interactions. This scoring system was called the 'combined score' method, and it was 
applied for the confidence calculations in the STRING database (von Mering., et al. 2005). 
This database is useful for searching predicted protein interactions detected by other 
methods, although the definitions are beyond the scope of this chapter. 
The score was calculated according to the formula (1): 
 1 (1 )ni
i E
score R

    (1) 
where score was the confidence value ranging from 0-1 with 1 equals to 100% accuracy, E was 
the set of methods under analysis (PEIMAP, PSIMAP, iPfam); Ri was the reliability of method 
i, and n was the number of interactions predicted by method i. The results of these calculations 
represented pairs of interactions with their respective confidence. With this information, it was 
possible to select those interactions that fulfilled a particular confidence threshold. In this case, 
a confidence score of 0.7 was chosen to select the core Leishmania major network. The threshold 
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selection can vary depending on how strongly supported the interactions were required. For 
us, a 0.70 confidence value gave a smooth fit to the power law distribution and this was an 
important condition for reliable detection of hubs and bottlenecks. 
2.2.3 Topological analysis of the network 
Topological metrics such as clustering coefficient and mean shortest path help to describe 
global characteristics of the network. They measure the density of the connections within the 
network. Highly dense connected networks are characterized by modular components 
which also maintain the robustness of the network against failures. Biological networks tend 
to have a modular structure (Jeong., et al. 2001) and one additional way to test for reliability 
of the predicted network is by comparing the values of the clustering coefficient and mean 
shortest path to randomly generated networks with the same number of nodes and edges. 
These metrics should be statistically different between predicted and random networks. In 
the case of Leishmania network, 1,000 random networks were generated and the metrics 
calculated and compared to the original network. 
The power law fitting for the definition of scale-free structure can be calculated using the 
plug-in Network Analyzer v.2.6.1(Assenov., et al. 2008) available in the platform Cytoscape 
(Shannon., et al. 2003). This platform includes a very advanced environment for network 
visualization and analysis. Network topology metrics, such as betweenness centrality, and 
connectivity were calculated using the Hubba server (http://hub.iis.sinica.edu.tw/ 
Hubbawebcite). (Lin., et al. 2008) A plug-in version of this tool in Cytoscape was recently 
made available. For the calculation of the metrics, the confidence scores of the interactions 
were used so the detection could be focused on the nodes most likely to be essential in the 
group of highly supported interactions. From this analysis, a potential list of targets was 
selected. However, it was possible that some proteins detected could also be conserved in 
terms of sequence and function among several organisms including humans. This 
becomes a problem if drugs targeting some of these proteins interfere with important 
biological process in humans, generating unwanted toxic effects. To avoid this, an 
additional filter was used for the list of predicted targets and it consisted of aligning the 
Leishmania proteins to the human proteins and excluding proteins that were conserved 
between these two species. 
2.2.4 Prediction of protein function from network clusters 
An important feature of network analysis was the prediction of protein function. The 
normal procedure for inferring function involved a homology search of the unknown 
protein versus a curated protein database such as UniProt (http://www.uniprot.org/). In 
some occasions, the detection of protein function was not feasible as significant similarity 
could not be found. When this approach failed, protein interaction network analysis helped 
to uncover potential functions. The prediction of protein function based on network analysis 
involved the assumption suggested by experimental data that interacting proteins tended to 
have related functions. This implied that it was possible to predict the function of 
neighboring nodes by clustering network modules and knowing the function of some of the 
nodes inside of the module. This analysis was carried out over the Leishmania network using 
the Markov Clustering (MCL) algorithm (Enright., et al. 2002) which has been demonstrated 
to be a robust and fast algorithm for detecting clusters or modules in protein networks 
(Brohee & van Helden 2006). The algorithm was implemented in the NeAT tool (Brohee., et 
www.intechopen.com
 
Current Topics in Tropical Medicine 
 
260 
al. 2008). For proteins of unknown function in the GeneDB database, we predicted their 
possible biological roles by evaluating the results of Gene Ontology terms for biological 
processes using the BinGO plug-in available in Cytoscape. 
2.2.5 Selection of candidate drug targets from the network analysis 
We constructed a protein-protein interaction (PPI) map, combining the results generated by 
PEIMAP, iPfam and PSIMAP (Fig. 2). The number of interactions detected for each database 
is described in (Table 1). By merging the data from the different approaches, bias to a 
specific class of interactions was avoided. The predicted network also contained isolated 
sub-networks which were difficult to analyze. These sub-networks appeared as a 
consequence of the inability to assign domains or from the lack of homology of those 
proteins to the known pairs of protein interactions. These sub-networks could be 
investigated by further experimental validation of the network. The total number of high 
confidence predicted interactions were 33,861 for 1,366 nodes 
 
Number of 
Proteins 
PEIMAP PSIMAP IPFAM 
8,335 
Nodes Edges Nodes Edges Nodes Edges 
718 14,839 3,184 158,984 2,336 50,398 
Table 1. Number of nodes and predicted interactions for each database. 
By using the topological metrics of connectivity and betweenness centrality we identified 
384 potential targets. From these targets, those that had homology to human proteins were 
eliminated. This substantially reduced the number of potential targets, although higher 
specificity of drug effects was expected. As explained earlier, toxicity becomes a very 
important issue when designing or searching for a drug, since many clinical trials failed 
because of undesired and severe side effects. After this filter, the final number of targets was 
reduced to 142. Further filters can be applied to this list to select those targets that were most 
attractive for drug design (Table 2).  
From the group of targets, 91 kinases were predicted as essential proteins in the network 
with no homology to the human kinome. Kinases are very important regulators of signaling 
in the cell, and in the case of Leishmania, kinases are crucial to enable the different metabolic 
changes needed to adapt to a human host. Perhaps by intensive pharmacological 
investigation, drugs that are very successful in treating cancer (e.g., Gleevec) could be used 
against Leishmania parasites. One particular example from the group of predicted kinases 
detected on the network is the protein LMPK (LmjF36.6470). This protein has been shown to be 
essential in Leishmania mexicana (Wiese 1998) and it has conserved orthologs in  other species 
such as L. amazonensis, L. major, L. tropica, L. aethiopica, L. donovani, L. infantum, and L. 
braziliensis (Wiese & Gorcke 2001). Therefore, this kinase was an interesting candidate for 
experimental validation and possibly its upstream and down-stream interacting partners 
could also be inhibited by a combination of drugs. In addition, one of the challenges in this 
disease is to find a broad-spectrum drug that can have therapeutic effects on several Leishmania 
species that cause different forms of leishmaniasis. Further analysis of this target can help to 
elucidate drugs or combination of drugs that are active against amastigotes, the stage 
responsible for the disease in mammals. Three ABC transporters that were Leishmania specific - 
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LmjF34.0670, LmjF27.0470, LmjF32.2060 - were also predicted as essential. They confer 
resistance to antimonials and pentamidine by extruding the drug outside of the cell (Perez-
Victoria., et al. 2002). Based upon our analysis, these proteins could be also interesting drug 
targets due to their role in the homeostasis of the intracellular parasite environment. 
 
 
Fig. 2. Visualization of the predicted Leishmania major interactome 
 
GeneDB ID Uniprot ID Description
LmjF15.0770 Q4QFA8 Protein kinase.
LmjF07.0250 Q4QIR9 Protein kinase
LmjF11.0330 Q4QH47 PIF1 helicase-like protein
LmjF35.2450 Q4FWM4 Hypothetical protein conserved  
LmjF25.1990 Q4Q9P0 Protein kinase
LmjF21.0853 Q4QCC1 Hypothetical protein conserved  
LmjF27.1800 Q4FYE1 Protein kinase-like
LmjF35.1000 Q4FX16 Casein kinase I
LmjF26.0660 Q4Q9C8 Protein disulfide isomerase
LmjF25.2050 Q4Q9N4 Helicase-like protein
Table 2. Top 10 list of predicted targets from the L. major interactome. 
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It has been shown that modular organization is a prevalent feature in biology, and this 
modular organization of pathways can be used to infer protein function (Rives & Galitski 
2003). We detected 63 clusters or modules in the network, and assigned potential biological 
processes to 263 proteins with no prior functional description. By examining the proportion 
of predicted targets by biological process, 64% of the proteins in the network were predicted 
to participate in the protein phosphorylation (GO:0006468). In addition, 8% of proteins were 
predicted to be involved in nucleosome assembly (GO:0006334), 4% in nucleic acid 
metabolic process (GO:0006139), 4% in electron transport (GO:0006118), 4% in transport 
processes (GO:0006810), and 2% in protein amino acid alkylation (GO:0006139). The 
remaining 14% of target proteins were distributed across processes with one protein per 
process. This result highlighted the importance of protein kinases as the main protein class 
to characterize and explore as drug targets in Leishmania parasites. 
3. Selection of drug targets by metabolic flux balance analysis and in silico 
deletions 
Proteins involved in metabolism constitute another important source of drug targets. The 
energetic balance in the cell is controlled by enzymes that regulate the transformation of 
substrates in a coordinated and efficient manner. These enzymes are needed specifically 
for producing energy or as building blocks for other molecules being essential for the 
viability of the organism. However, a different approach needs to be used for modeling 
metabolism because the interactions between enzymes depend upon the rate of turnover 
of molecules or fluxes, not specifically through physical interactions as described for the 
case of the interactome. 
The reconstruction of metabolic networks is more established compared to interactome 
generation. Since glycolysis was elucidated in 1930, several metabolic pathways have been 
discovered in many organisms. Metabolic networks reconstructed from this source of data 
started with E. coli (Reed & Palsson 2003) and was followed later on by reconstructions in 
eukaryotic organisms such as Saccharomyces  cerevisiae (Duarte., et al. 2004) and Aspergillus 
niger (David., et al. 2003). More recently, metabolic networks of Plasmodium falciparum 
(Plata., et al. 2010) and Leishmania major (Chavali., et al. 2008) were reconstructed with the 
aim of detecting drug targets, and some details about the network generation and analysis 
will be discussed. 
In order to build a metabolic network it is necessary to list all the substances with their 
concentrations and the reactions between substances. In living systems these reactions are 
catalyzed by enzymes and the transport processes are carried out by transporters or 
channels. The reactions are influenced by the stoichiometric coefficients which denote the 
proportion of substrate and product molecules involved in a reaction. The reaction: 
S1 + S1 → 2P 
describes the generation of product P from S1. Therefore, the stoichiometric coefficients for 
this particular reaction are -1,-1 and 2 respectively. For a metabolic network consisting of m 
substances and r reactions, the systems dynamics are described by systems equations (2) (or 
balance equations, since the balance of substrate production and degradation is considered):  
 
1
r
ij j
j
dSi
n v
dt 
  (2) 
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The term nij are the stoichiometric coefficients of metabolite i in reaction j. In this case, 
diffusion is not considered in the system. These equations can be applied to compartments, 
where the flux between compartments has to be considered as a different reaction. The 
stoichiometric coefficients nij can be combined into the so-called stoichiometric matrix, where 
each column belongs to a reaction and each row to a substance (Klipp et al., 2005). 
According to this, a mathematical model for a metabolic network can be described as a 
system with a vector S = (S1, S2, …, Sn) of concentration values for the different species, a 
vector v = (v1, v2, …, vr ) of reaction rates and the stoichiometric matrix N. With these 
definitions, the balance equation (3) can be rewritten as follows: 
 
dS
Nv
dt
  (3) 
3.1 Predicted drug targets in the Leishmania major metabolic network 
The total number of genes included in the network was 560, with 1,112 reactions and 1,101 
metabolites. The process for the reconstruction involved different data sources, in particular 
literature and biological databases. Reaction stoichiometry and subcellular localization were 
also extracted by examining the existing literature. Some reactions were assigned as non-
gene-associated to account for spontaneously generated metabolites. The gene-associated 
reactions were further adjusted according to the specified constraints.  
Flux balance analysis is a method that has been used extensively to analyze metabolic 
networks. The important advantage of this method is that does not require detailed 
knowledge of the enzyme kinetics. The principle of the method relies on investigation of the 
fluxes that have the greatest influence in the growth (or production of biomass) by 
preserving a set of constraints such as physicochemical, thermodynamic, topological and 
environmental. In the case of the Leishmania model, constraints included reaction 
reversibility rules, promastigote/amastigote protein expression data, various medium 
conditions and prevalence of transport reactions across cellular compartments were used. 
The model was simulated under steady state conditions, which means that the net change of 
any metabolite in the network during time should be zero. 
Virtual knockouts were carried out over the network with the aim to detect potential drug 
targets. The knockout genes were classified as being lethal (essential for survival), growth 
reducing, or with no effect. From this analysis, only 12% of single knockouts were predicted 
as lethal and 10% as growth reducing. Approximately 83% of all lethal genes belonged to 
three metabolic processes: lipid, carbohydrate or amino-acid metabolism, highlighting how 
critical these are to general function. 
From the group of lethal genes, the authors selected those that were exclusive or without 
human orthologs as potential candidates (a strategy that was also employed for the 
interactome analysis). The gene LmjF05.0350, which encodes for trypanothione reductase, 
was lethal in silico. This enzyme participates in the reduction of oxidative agents by using 
trypanothione and this molecule is only present in kinetoplastids. This enzyme has been 
studied extensively as drug target, confirming the predictions of the mathematical model 
(Eberle., et al. 2011). LmjF31.2940 and LmjF21.0845, encoding for squalene synthase and 
hypoxanthine-guanine phosphoribosyltransferase respectively, were also predicted as lethal 
in the network. The squalene synthase inhibitors affect the sterol biosynthesis pathway, 
taking advantage of the trypanosomatid requirement for specific endogenous sterols (e.g. 
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ergosterol). Interestingly, proteins belonging to this process in Leishmania were also detected 
by homology and interactome analysis showing consistency between methods. 
Double knockouts were also simulated to identify lethal combination of genes. Out of 
152,520 double deletions, 19,341 were lethal. From this group, 19,285 double deletions were 
trivial lethal, which means that at least one of the genes involved was lethal in a single 
deletion. There were 56 non-trivial lethal double deletions that could be interesting to test 
experimentally. The main participation of these double knockouts was in the lipid and 
carbohydrate metabolism with 57.6% of the genes in these groups. One explanation for the 
large number of double deletions that were not essential is the high degree of redundancy in 
the network. These results show the utility of a different methodology that uses 
mathematical modeling for the detection of essential genes in metabolism. 
4. Discovery of new drugs using virtual screening 
Once the protein target is identified, the next step is finding an effective and non-toxic 
inhibitor that can be administrated in human patients. However, the process for identifying 
compounds, as in the case for drug targets, requires expensive equipment for testing 
millions of chemicals with a final result of few hits that can advance in further drug 
development stages. This process is unpractical and time consuming. A computational 
strategy has been used to improve the drug search by using computational chemistry to 
select those compounds that are likely to work in the experimental setting, this 
computational technique is called virtual screening. The aim of this technique is to identify 
novel small molecules that could bind the target of interest. This is carried out by docking 
compound libraries over the protein structure of the target, using optimization algorithms 
that search for the best conformation of the target and the ligand, which by definition has 
the lowest conformational energy (McInnes 2007). The libraries are usually compounds 
available from chemical vendors or predicted in some cases. 
The procedure for virtual screening involves the selection of the target as a first step. The 
target can be chosen by the results from RNAi screenings or from computational approaches 
as the ones previously described. The target must have a 3D structure with an acceptable 
resolution, which is critical for the accuracy of the predictions. The structures determined by 
experimental methods can be easily accessed through the Protein Data Bank (PDB; 
http://www.pdb.org/). This database contains protein structures from different organisms 
determined by X-ray crystallography or NMR methods. In addition, predicted structures by 
homology-modeling methods can be found in the ModBase database 
(http://modbase.compbio.ucsf.edu/) (Pieper., et al. 2009). In contrast, the resources for 
compounds or ligands are restricted due to patent protection. However an interesting 
resource that contains millions of ligands ready to use for virtual screening experiments is 
the ZINC database (http://zinc.docking.org/) (Irwin & Shoichet 2005). This database 
includes commercial ligands and it is also free for academic use. This combination of 
resources of protein structures and ligand databases facilitates enormously the development 
of virtual screening projects which can be very productive for finding new drugs, especially 
for neglected diseases such as leishmaniasis. 
The tools employed for virtual screening are also very diverse. One very popular tool is 
AutoDock (Goodsell., et al. 1996), which was developed by the Scripps Institute and used in 
several virtual screening projects, demonstrating good performance and accuracy. However, 
a recent study (Chang., et al. 2010) compared the accuracy and reproducibility of AutoDock 
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against a recently developed tool, also freely available, called AutoDock Vina (Trott & Olson 
2010). The experiments consisted of screening ligands with known activity against the HIV 
protease and decoys or non-binders. Autodock Vina performed very well in terms of speed, 
being ~10 times faster, and more accurate in ranking larger molecules compared to 
AutoDock. We are currently using AutoDock Vina in a virtual screening project called 
"Drug Search for Leishmaniasis" in association with IBM-World Community Grid 
(http://www.worldcommunitygrid.org/research/dsfl/overview.do) to speed up the 
process of finding new active compounds. 
As an example of the application of this strategy in Leishmania, a recent study demonstrated 
the utility of virtual screening to identify potential MAPK inhibitors. The target, MAPK was 
first modeled by using homology modeling techniques. Essentially, the technique predicts the 
3D structure of a particular protein by finding sequence homology to a model protein with 
experimentally determined structure. This model was refined by molecular dynamics. 
Structural features, such as ATP binding pocket, phosphorylation lip, and common docking 
site were identified. Virtual screening was carried out using this target with several 
compounds from the class of ATP inhibitors. Interestingly, the docking analysis suggested 
that the indirubin class of molecules could act as putative inhibitors of Leishmania MAPK. By 
testing this result experimentally, the authors found reasonably good correlation between in 
vitro activity and calculated binding energy for indirubin class of inhibitors obtained in the 
virtual screening study. These molecules make strong hydrogen bonding interactions with 
Lys43, Arg57, Asp155, Glu94, and Ile96 amino acid residues of the Leishmania MAPK model. 
These residues belong to the catalytic domain and inhibition of the catalytic domain leads to 
impaired kinase activity (Awale., et al. 2010). This is a clear example of the synergy between 
computational and experimental methods to accelerate drug discovery. 
5. Selection of new drugs using machine learning techniques 
The Leishmania proteome is estimated to contain ~8,150 proteins based on the annotated 
genome of the sequenced species (Peacock., et al. 2007). However, fewer than 150 proteins 
have 3D structures in the PDB. This limits the use of docking-based strategies to search for 
anti-Leishmania compounds. An alternative strategy to associate active compounds with 
Leishmania targets is by using machine learning techniques. This approach is intended to find 
patterns on protein targets such as domains, post-translational modifications etc, that can be 
linked to a specific class of compounds. This system will “learn” these patterns and when 
challenged by proteins from the organism of interest it will predict the potential association for 
a particular compound. Two studies have applied this strategy to a particular set of protein 
targets (Bulashevska., et al. 2009; Thangudu., et al. 2010), employing the different techniques 
such as support vector machines (SVM) and Bayesian classifiers (BC). As a perspective, these 
methods could also be applied for drug search in Leishmania; however, the definition of protein 
patterns would be critical for establishing robust drug-target relationships. 
6. Experimental approaches for drug testing in Leishmania 
Several in vitro assays to test Leishmania susceptibility to new potential inhibitors have been 
developed for the two stages of Leishmania, namely promastigotes and amastigotes. These 
two stages are morphologically and biochemically different and these differences are likely 
responsible for their differing susceptibility to proven anti-leishmanial compounds. Assays 
developed with intracellular amastigotes have the advantage of being more “disease 
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appropriate” since this is the stage responsible for mammalian disease. In addition, an 
intracellular in vitro model resembles the natural event when the parasite is in the 
mammalian host. Axenic amastigotes are also employed, although a more efficient 
alternative is the use of intracellular fluorescent or bioluminescent amastigotes. 
The effectiveness of compounds to kill the parasites has been evaluated using different 
methodological approaches. Several years ago, direct parasite counting was the most used 
method (Gaspar., et al. 1992; Chan-Bacab., et al. 2003; Khan., et al. 2003). However, this 
method lacked accuracy and precision, likely due to human errors. This made necessary to 
develop new automated methods based on colorimetric, radioactive, fluorescent and 
luminometer detection (Fumarola., et al. 2004). Colorimetric methods like MTT [3-(4,5-
dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] have been used frequently. 
Recently, these methods are being replaced by transgenic parasites with reporter genes that 
do not interfere with cellular mitochondria. Parasites genetically engineered to express 
green fluorescent protein (GFP) or luciferase, have been developed and are currently used in 
automatized protocols involving flow cytometer or luminometer. 
On the other hand, it is important to measure cytotoxicity to evaluate the possibility that a 
compound might produce side effects in humans. Mammalian or mouse cell lines are 
usually employed in these assays. The most used cells are U-937 human histiocytes, TPH-
1 human peripheral blood monocytes, and hamster peritoneal macrophages (Robledo., et 
al. 1999; Weniger., et al. 2001; Varela., et al. 2009; Taylor., et al. 2010). To increase the 
selectivity of promising drugs, liposomal formulations of the compounds may be 
evaluated in order to reduce the toxicity as was observed for amphotericin B (Mehta., et 
al. 1985; Lopez-Berestein 1987). 
The leishmanicidal activity of compounds that show high anti-leishmanial activity and low 
toxicity for mammalian cells in vitro, is next evaluated in vivo. This is normally performed in 
mouse or the golden hamster (Mesocricetus auratus) models depending on the Leishmania 
subgenus (Travi., et al. 2002). Monkey models can also used but these studies are limited to 
only a few laboratories worldwide (Grimaldi., et al. 2010). 
7. Conclusion 
Through the current chapter, the more relevant techniques for finding drugs and targets 
employing computational approaches were described. Special considerations should be 
made when using the homology searching approach for finding drug targets as the context 
of protein interactions is important for the definition of essentiality. Protein interaction 
network analysis together with metabolic flux balance analysis are becoming useful 
alternatives to understand protein function and to systematically select drug targets. The 
selection of new inhibitory compounds can be done by using virtual screening. Predicted 
structures can also be used in virtual screening when experimentally derived structures 
are  absent. Finally, machine learning techniques are a promising option to search for anti-
leishmanial drugs, especially when experimental or predicted structures are not available, 
as may occur with many Leishmania proteins. It is important to state that any 
computational analysis is considered exploratory, and experimental validation is 
necessary to guide final decisions about potential compounds that can advance to the next 
stage of drug discovery. However, by using computational tools the search space for 
drugs and targets is reduced, allowing more focused experiments that could reduce the 
cost and time of drug development. 
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